Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 778-786

  Grienke, Ulrike ^a   Schmidtke, Michaela ^b   Kirchmair, Johannes ^a   Pfarr, Kathrin ^b   Wutzler, Peter ^b   Dürrwald, Ralf ^c   Wolber, Gerhard ^a   Liedl, Klaus R ^a   Stuppner, Hermann ^a   Rollinger, Judith M ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c IDT Biologika GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; KATSUMADAIN A; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ALPINIA; ALPINIA KATSUMADAI; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG ISOLATION; ENZYME INHIBITOR INTERACTION; IC 50; INFLUENZA VIRUS A H1N1; MOLECULAR DOCKING; NONHUMAN; PHYTOCHEMISTRY; VIRUS INHIBITION;

ALPINIA; ANTIVIRAL AGENTS; DIARYLHEPTANOIDS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INHIBITORY CONCENTRATION 50; MOLECULAR DYNAMICS SIMULATION; NEURAMINIDASE; PHYTOTHERAPY; PLANTS, MEDICINAL; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77249115238     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901440f     Document Type: Article

References (53)

1. Memoli, M. J.; Morens, D. M.; Taubenberger, J. K. Pandemic and seasonal influenza: therapeutic challenges. Drug Discovery Today 2008, 13, 590-595.
2. von Itzstein, M. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discovery 2007, 6, 967-974.
3. Moscona, A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353, 1363-1373.
4. Matrosovich,M. N.; Matrosovich, T. Y.; Gray, T.; Roberts, N. A.; Klenk, H.-D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 2004, 78, 12665-12667.
5. Hayden, F. G.; Hay, A. J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 1992, 176, 119-130.
6. Klimov, A. I.; Rocha, E.; Hayden, F. G.; Shult, P. A.; Roumillat, L. F.; Cox, N. J. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: Detection by polymerase chain reaction-restriction analysis. J. Infect. Dis. 1995, 172, 1352-1355.
7. Shiraishi, K.; Mitamura, K.; Sakai-Tagawa, Y.; Goto, H.; Sugaya, N.; Kawaoka, Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J. Infect. Dis. 2003, 188, 57-61.
8. Simonsen, L.; Viboud, C.; Grenfell, B. T.; Dushoff, J.; Jennings, L.; Smit, M.; Macken, C.; Hata, M.; Gog, J.; Miller, M. A.; Holmes, E. C. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol. 2007, 24, 1811-1820.
9. Schmidtke, M.; Bauer, K.; Ludwig, N.; Wutzler, P. Emergence and phylogenetic relationships of amantadine-resistant human H3N2 influenza A viruses in Germany in the season 2005/2006. Int. J. Antimicrob. Agents 2008, 32, 192-195.
10. Nelson Martha, I.; Simonsen, L.; Viboud, C.; Miller Mark, A.; Holmes Edward, C. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 2009, 388, 270-278.
11. Deyde, V. M.; Xu, X.; Bright, R. A.; Shaw, M.; Smith, C. B.; Zhang, Y.; Shu, Y.; Gubareva, L. V.; Cox, N. J.; Klimov, A. I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196, 249-257.
12. Barr, I. G.; Hurt, A. C.; Deed, N.; Iannello, P.; Tomasov, C.; Komadina, N. The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006. Antivir. Res. 2007, 75, 173-176.
13. Schmidtke, M.; Zell, R.; Bauer, K.; Krumbholz, A.; Schrader, C.; Suess, J.; Wutzler, P. Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenzaAviruses isolated in Germany between 1981 and 2001. Intervirology 2006, 49, 286-293.
14. Krumbholz, A.; Schmidtke, M.; Bergmann, S.; Motzke, S.; Bauer, K.; Stech, J.; Duerrwald, R.; Wutzler, P.; Zell, R. High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J. Gen. Virol. 2009, 90, 900-908.
15. Hayden, F. G. Antivirals for influenza: Historical perspectives and lessons learned. Antivir. Res. 2006, 71, 372-378.
16. Bauer, K.; Richter, M.; Wutzler, P.; Schmidtke, M. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006. Antivir. Res. 2009, 82, 34-41.
17. Meijer, A.; Lackenby, A.; Hungnes, O.; Lina, B.; van-der-Werf, S.; Schweiger, B.; Opp, M.; Paget, J.; van-de-Kassteele, J.; Hay, A.; Zambon, M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 2009, 15, 552-560.
18. Moscona, A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 2009, 360, 953-956.
19. Weinstock, D. M.; Zuccotti, G. The evolution of influenza resistance and treatment. JAMA, J. Am. Med. Assoc. 2009, 301, 1066-1069.
20. Collins, P. J.; Haire, L. F.; Lin, Y. P.; Liu, J.; Russell,R. J.; Walker, P. A.; Skehel, J. J.; Martin, S. R.; Hay, A. J.; Gamblin, S. J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature (London) 2008, 453, 1258-1261.
21. Itoh, Y.; Shinya, K.; Kiso, M.; Watanabe, T.; Sakoda, Y.; Hatta, M.; Muramoto, Y.; Tamura, D.; Sakai-Tagawa, Y.; Noda, T.; Sakabe, S.; Imai, M.; Hatta, Y.; Watanabe, S.; Li, C.; Yamada, S.; Fujii, K.; Murakami, S.; Imai, H.; Kakugawa, S.; Ito, M.; Takano, R.; Iwatsuki-Horimoto, K.; Shimojima, M.; Horimoto, T.; Goto, H.; Takahashi, K.; Makino, A.; Ishigaki, H.; Nakayama, M.; Okamatsu, M.; Takahashi, K.; Warshauer, D.; Shult, P. A.; Saito, R.; Suzuki, H.; Furuta, Y.; Yamashita, M.; Mitamura, K.; Nakano, K.; Nakamura, M.; Brockman-Schneider, R.; Mitamura, H.; Yamazaki, M.; Sugaya, N.; Suresh, M.; Ozawa, M.; Neumann, G.; Gern, J.; Kida, H.; Ogasawara, K.; Kawaoka, Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature (London) 2009, 460, 1021-1025.
22. Liu, A.-L.; Wang, Y.-T.; Du, G.-H. Neuraminidase as a target for drugs for the treatment of influenza. Drugs Future 2005, 30, 799-806.
23. Berman, H. M.; Westbrook, J.; Zardecki, C.; Bourne, P. E. The protein data bank. Protein Struct. 2003, 389-405.
24. Myers, R. W.; Lee, R. T.; Lee, Y. C.; Thomas, G. H.; Reynolds, L. W.; Uchida, Y. The synthesis of 4-methylumbelliferyl alphaketoside of N-acetylneuraminic acid and its use in a fluorometric assay for neuraminidase. Anal. Biochem. 1980, 101, 166-174.
25. Lee, C. H.; Kim, S. I.; Lee, K. B.; Yoo, Y. C.; Ryu, S. Y.; Song, K. S. Neuraminidase inhibitors from Reynoutria elliptica. Arch. Pharm. Res. 2003, 26, 367-374.
26. Wang, Z.; Huang, W.; Li, Y. Antiviral activity of extracts from Alpinia. Canadian Patent CN 16988472005, 2005.
27. Wu, J. Manufacture of traditional Chinese medicine with antiviral, anti-inflammatory, and detoxicating effects. Canadian Patent CN 18401472006, 2006.
28. Wang, X.; Wang, L. Topical chinese medicinal preparation with good antiviral effect. Canadian Patent CN 1012191962008, 2008.
29. Bensky, D.; Clavey, S.; Stöger, E.; Gamble, E. Chinese Herbal Medicine - Materia Medica. 3rd ed.; Eastland Press, Inc.: Seattle, 2004; pp 485-486.
30. Kuroyanagi, M.; Noro, T.; Fukushima, S.; Aiyama, R.; Ikuta, A.; Itokawa, H.; Morita, M. Studies on the constituents of the seeds of Alpinia katsumadai Hayata. Chem. Pharm. Bull. 1983, 31, 1544-1550.
31. Yang, Y.; Kinoshita, K.; Koyama, K.; Takahashi, K.; Tai, T.; Nunoura, Y.; Watanabe, K. Two novel anti-emetic principles of Alpinia katsumadai. J. Nat. Prod. 1999, 62, 1672-1674.
32. Suksamrarn, A.; Ponglikitmongkol, M.; Wongkrajang, K.; Chindaduang, A.; Kittidanairak, S.; Jankam, A.; Yingyongnarongkul, B.-e.; Kittipanumat, N.; Chokchaisiri, R.; Khetkam, P.; Piyachaturawat, P. Diarylheptanoids, new phytoestrogens from the rhizomes of Curcuma comosa: isolation, chemical modification and estrogenic activity evaluation. Bioorg. Med. Chem. 2008, 16, 6891-6902.
33. Sheu, T. G.; Deyde, V. M.; Okomo-Adhiambo, M.; Garten, R. J.; Xu, X.; Bright, R. A.; Butler, E. N.; Wallis, T. R.; Klimov, A. I.; Gubareva, L. V. Surveillance for neuraminidase inhibitor resistance among human Influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 2008, 52, 3284-3292.
34. Bauer, K.; Schrader, C.; Suess, J.; Wutzler, P.; Schmidtke, M. Neuraminidase inhibitor susceptibility of porcine H3N2 influenza Aviruses isolated in Germany between 1982 and 1999. Antivir. Res. 2007, 75, 219-226.
35. Russell, R. J.; Haire, L. F.; Stevens, D. J.; Collins, P. J.; Lin, Y. P.; Blackburn, G. M.; Hay, A. J.; Gamblin, S. J.; Skehel, J. J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443, 45-49.
36. Amaro, R. E.; Cheng, X. L.; Ivanov, I.; Xu, D.; McCammon, J. A. Characterizing Loop Dynamics and Ligand Recognition in Human-and Avian-Type Influenza Neuraminidases via Generalized Born Molecular Dynamics and End-Point Free Energy Calculations. J. Am. Chem. Soc. 2009, 131, 4702-4709.
37. Amaro, R. E.; Minh, D. D. L.; Cheng, L. S.; Lindstrom, W. M.; Olson, A. J.; Lin, J. H.; Li, W. W.; McCammon, J. A. Remarkable Loop Flexibility in Avian Influenza N1 and Its Implications for Antiviral Drug Design. J. Am. Chem. Soc. 2007, 129, 7764-7765.
38. Cheng, L. S.; Amaro, R. E.; Xu, D.; Li, W. W.; Arzberger, P. W.; McCammon, J. A. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J. Med. Chem. 2008, 51, 3878-3894.
39. Abagyan, R.; Totrov, M.; Kuznetsov, D. ICM - a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem. 1994, 15, 488-506.
40. An, J. H.; Lee, D. C. W.; Law, A. H. Y.; Yang, C. L. H.; Poon, L. L. M.; Lau, A. S. Y.; Jones, S. J. M. A Novel Small-Molecule Inhibitor of the Avian Influenza H5N1 Virus Determined through Computational Screening against the Neuraminidase. J. Med. Chem. 2009, 52, 2667-2672.
41. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
42. Case, D. A.; Darden, T. A.; Cheatham, T. E.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Crowley, M.; Walker, R. C.; Zhang, W.; Merz, K. M.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Kolossváry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Mathews, D. H.; Seetin, M. G.; Sagui, C.; Babin, V.; Kollman, P. A. AMBER10; University of California: San Francisco, CA, 2008.
43. Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions. J. Med. Chem. 2006, 49, 5912-5931.
44. Zaraket, H.; Saito, R.; Sato, I.; Suzuki, Y.; Li, D.; Dapat, C.; Caperig-Dapat, I.; Oguma, T.; Sasaki, A.; Suzuki, H. Molecular evolution of human influenza A viruses in a local area during eight influenza epidemics from 2000 to 2007. Arch. Virol. 2009, 154, 285-295.
45. Schmidtke, M.; Riabova, O.; Dahse, H. M.; Stelzner, A.; Makarov, V. Synthesis, cytotoxicity and antiviral activity ofN,N′-bis-5- nitropyrimidyl derivatives of dispirotripiperazine. Antivir. Res. 2002, 55, 117-127.
46. Dolinsky, T. J.; Nielsen, J. E.; McCammon, J. A.; Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004, 32, W665-W667.
47. Dolinsky, T. J.; Czodrowski, P.; Li, H.; Nielsen, J. E.; Jensen, J. H.; Klebe, G.; Baker, N. A. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 2007, 35, W522-W525.
48. Humphrey, W.; Dalke, A.; Schulten, K. VDM: visual molecular dynamics. J. Mol. Graphics 1996, 14, 33-38, plates, 27-28.
49. Shao, J. Y.; Tanner, S. W.; Thompson, N.; Cheatham, T. E. Clustering molecular dynamics trajectories: 1. Characterizing the performance of different clustering algorithms. J. Chem. Theory Comput. 2007, 3, 2312-2334.
50. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic generation of 3D atomic coordinates for organic molecules. Tetrahedron Comput. Methodol. 1990, 3, 537-547.
51. Sadowski, J.;Rudolph,C.;Gasteiger, J.The generation of 3Dmodels of host-guest complexes. Anal. Chim. Acta 1992, 265, 233-241.
52. Sadowski, J.; Gasteiger, J.; Klebe, G. Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures. J. Chem. Inf. Comput. Sci. 1994, 34, 1000-1008.
53. DeLano, W. L. The PyMOL Molecular Graphics System, version 1.0; DeLano Scientific: Palo Alto, CA, 2002.